Business Description
Gilead Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US3755581036
Share Class Description:
LIM:GILD: Ordinary SharesCompare
Compare
Traded in other countries / regions
GILD.USA0QYQ.UKGIS.GermanyGILD.MexicoGILD.Argentina1GILD.ItalyGILD.PeruGILD.ChileGILD34.BrazilGILD.Austria IPO Date
2021-02-03Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 1.26 | |||||
| Debt-to-EBITDA | 5.93 | |||||
| Interest Coverage | 7.79 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.87 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.3 | |||||
| 3-Year EBITDA Growth Rate | 36.6 | |||||
| 3-Year EPS without NRI Growth Rate | -1.8 | |||||
| 3-Year FCF Growth Rate | -0.3 | |||||
| 3-Year Book Growth Rate | 8.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 2.31 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 99.92 | |||||
| 14-Day RSI | 99.58 | |||||
| 6-1 Month Momentum % | 38.65 | |||||
| 12-1 Month Momentum % | 27.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | |||||
| Quick Ratio | 1.1 | |||||
| Cash Ratio | 0.43 | |||||
| Days Inventory | 99.33 | |||||
| Days Sales Outstanding | 60.28 | |||||
| Days Payable | 34.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.2 | |||||
| Dividend Payout Ratio | 0.69 | |||||
| 3-Year Dividend Growth Rate | 3.3 | |||||
| Forward Dividend Yield % | 3.2 | |||||
| 5-Year Yield-on-Cost % | 4.18 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 4.7 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.11 | |||||
| Operating Margin % | 27 | |||||
| Net Margin % | 0.45 | |||||
| FCF Margin % | 33.33 | |||||
| ROE % | 0.63 | |||||
| ROA % | 0.22 | |||||
| ROIC % | 10.05 | |||||
| ROC (Joel Greenblatt) % | 21.02 | |||||
| ROCE % | 2.51 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1037.78 | |||||
| Forward PE Ratio | 12.77 | |||||
| PE Ratio without NRI | 21.08 | |||||
| Shiller PE Ratio | 15.58 | |||||
| PEG Ratio | 3.98 | |||||
| PS Ratio | 4.13 | |||||
| PB Ratio | 6.3 | |||||
| Price-to-Free-Cash-Flow | 12.4 | |||||
| Price-to-Operating-Cash-Flow | 11.67 | |||||
| EV-to-EBIT | 116.86 | |||||
| EV-to-Forward-EBIT | 10.72 | |||||
| EV-to-EBITDA | 34.49 | |||||
| EV-to-Forward-EBITDA | 9.83 | |||||
| EV-to-Revenue | 4.78 | |||||
| EV-to-Forward-Revenue | 4.75 | |||||
| EV-to-FCF | 14.15 | |||||
| Price-to-Projected-FCF | 1.2 | |||||
| Price-to-Median-PS-Value | 1.12 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.86 | |||||
| Earnings Yield (Greenblatt) % | 0.86 | |||||
| FCF Yield % | 7.98 | |||||
| Forward Rate of Return (Yacktman) % | 14.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gilead Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 28,298 | ||
| EPS (TTM) ($) | 0.09 | ||
| Beta | 0 | ||
| Volatility % | 22.76 | ||
| 14-Day RSI | 99.58 | ||
| 14-Day ATR ($) | 0.079203 | ||
| 20-Day SMA ($) | 96.32 | ||
| 12-1 Month Momentum % | 27.02 | ||
| 52-Week Range ($) | 69.47 - 96.66 | ||
| Shares Outstanding (Mil) | 1,246.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gilead Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gilead Sciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gilead Sciences Inc Frequently Asked Questions
What is Gilead Sciences Inc(LIM:GILD)'s stock price today?
The current price of LIM:GILD is $96.32. The 52 week high of LIM:GILD is $96.66 and 52 week low is $69.47.
When is next earnings date of Gilead Sciences Inc(LIM:GILD)?
The next earnings date of Gilead Sciences Inc(LIM:GILD) is 2025-02-06 Est..
Does Gilead Sciences Inc(LIM:GILD) pay dividends? If so, how much?
The Dividend Yield %  of Gilead Sciences Inc(LIM:GILD) is 3.2% (As of Today), Highest Dividend Payout Ratio of Gilead Sciences Inc(LIM:GILD) was 0.69. The lowest was 0.1. And the median was 0.38. The  Forward Dividend Yield % of Gilead Sciences Inc(LIM:GILD) is 3.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers